57 completed, 11 recruiting, 8 terminated, 5 unknown. 49 Phase 2, 18 Phase 1, 17 Phase 3, 1 Not applicable, 1 Phase 4.
Follow Trabectedin: new trials by email Literature Review of Trabectedin trials Research Report on Trabectedin
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Phase I Study of Pazopanib in Combination With Trabectedin, Ipilimumab and Nivolumab (TraPIN) in Pediatric and Young Adult Patients With Recurrent Soft Tissue Sarcomas Pazopanib, Trabectedin, Ipilimumab - Soft Tissue Sarcomas | Phase 1 | Recruiting | M.D. Anderson Cancer Center | 18 | 2026-06-12 | 2026-08-06 |
| Phase II Decentralized Pragmatic Trial of Adjuvant Doxorubicin - Trabectedin Chemotherapy in uLMS Trabectedin, Doxorubicin Hydrochloride - Uterine Leiomyosarcoma | Phase 2 | Recruiting | M.D. Anderson Cancer Center | 48 | 2025-10-02 | 2026-10-13 |
| Interest of Post-operative Chemotherapy in Patients With Localised Uterine Leiomyosarcoma Suspected of Having a High Risk of Recurrence Based on a Biological Test Performed on the Tumour Doxorubicin, Trabectedin - Leiomyosarcoma Uterus | Phase 2 | Recruiting | UNICANCER | 198 | 2025-01-27 | 2026-09-29 |
| A Study to Investigate Efficacy & Safety of Intratumoral INT230-6 Compared to US Standard of Care in Adults With Soft Tissue Sarcomas (INVINCIBLE-3) INT230-6, Eribulin, Trabectedin - Sarcoma,Soft Tissue | Phase 3 | Recruiting | Intensity Therapeutics, Inc. | 333 | 2024-06-28 | 2026-08-11 |
| Testing Olaparib and Temozolomide Versus the Usual Treatment for Uterine Leiomyosarcoma After Chemotherapy Has Stopped Working Biospecimen Collection, Bone Scan, Computed Tomography - Locally Advanced Uterine Corpus Leiomyosarcoma, Metastatic Uterine Corpus Leiomyosarcoma | Phase 2 / Phase 3 | Active not recruiting | National Cancer Institute (NCI) | 74 | 2023-03-30 | 2026-10-01 |
| Study on Trabectedin in Combination With Pioglitazone in Patients Myxoid Liposarcomas With Stable Disease After T Alone. Trabectedin, Pioglitazone Oral Product - Liposarcoma, Myxoid, Liposarcoma, Dedifferentiated | Phase 2 | Completed | Mario Negri Institute for Pharmacological Research | 10 | 2022-02-02 | 2026-02-18 |
| Trial in Patients With Metastatic or Locally Advanced Leiomyosarcoma Trabectedin, Gemcitabine, No Intervention: Observational Cohort - Leiomyosarcoma of Ovary, Soft Tissue Sarcoma | Phase 2 | Recruiting | Italian Sarcoma Group | 100 | 2021-10-29 | 2026-03-25 |
| tTF-NGR Randomized Study - STS Trabectedin, tTF-NGR - Soft Tissue Sarcoma | Phase 3 | Recruiting | Universität Münster | 126 | 2021-10-26 | 2025-04-04 |
| Retrospective Multicenter Study of Elderly Patients With Ovarian Cancer Treated With Trabectedin and PLD Trabectedin and PLD - Ovarian Cancer | Completed | Grupo Español de Investigación en Cáncer de Ovario | 43 | 2021-10-21 | 2023-05-24 | |
| Study on Trabectedin in Advanced Rearranged Mesenchymal Chondrosarcoma Trabectedin - Mesenchymal Chondrosarcoma | Phase 2 | Recruiting | Italian Sarcoma Group | 16 | 2021-09-14 | 2026-03-27 |
| Metronomic Trabectedin, Gemcitabine, and Dacarbazine for Soft Tissue Sarcoma Trabectedin - Leiomyosarcoma | Phase 2 | Recruiting | Sarcoma Oncology Research Center, LLC | 80 | 2021-09-09 | 2025-02-24 |
| Treatment of Milademetan Versus Trabectedin in Patient With Dedifferentiated Liposarcoma RAIN-32, Trabectedin - Dedifferentiated Liposarcoma | Phase 3 | Terminated | Rain Oncology Inc | 175 | 2021-07-14 | 2025-01-14 |
| Multicohort Trial of Trabectedin and Low-dose Radiation Therapy in Advanced/Metastatic Sarcomas Trabectedin - Soft Tissue Sarcoma, Bone Tumors | Phase 2 | Unknown | Grupo Espanol de Investigacion en Sarcomas | 85 | 2021-05-28 | 2023-03-27 |
| SARC037: A Phase I/II Study to Evaluate the Safety of Trabectedin in Combination With Irinotecan in Ewing Sarcoma Patients Trabectedin 1 MG [Yondelis], Irinotecan, tumor biopsy - Ewing Sarcoma | Phase 1 / Phase 2 | Completed | Sarcoma Alliance for Research through Collaboration | 37 | 2021-01-05 | 2025-12-17 |
| Trabectedin in Combination With Olaparib in Advanced Unresectable or Metastatic Sarcoma Olaparib, Trabectedin - Sarcoma, Sarcoma Metastatic | Phase 2 | Completed | University of Michigan Rogel Cancer Center | 29 | 2020-03-17 | 2025-08-29 |
| Prospective Identification of Predictive Biomarkers of Trabectedin Efficacy in Non-L Soft-tissue Sarcoma Patients Trabectedin - Soft Tissue Sarcoma Adult, Undifferentiated Pleomorphic Sarcoma | Not applicable | Completed | Institut Bergonié | 29 | 2020-01-06 | 2026-03-06 |
| Evaluation of Symptom Benefit Rate of Trabectedin/PLD in Patients With Recurrent Ovarian Cancer Carboplatin, Gemcitabine, Bevacizumab - Recurrent Ovarian Carcinoma | Phase 3 | Terminated | AGO Research GmbH | 9 | 2019-08-09 | 2022-02-24 |
| Trabectedin and Venetoclax in Treating Patients With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma Resistant or Intolerant to a BTK Inhibitor Trabectedin, Venetoclax - Refractory Chronic Lymphocytic Leukemia, Refractory Small Lymphocytic Lymphoma | Phase 1 | Withdrawn | M.D. Anderson Cancer Center | 2019-06-18 | 2023-09-25 | |
| Trabectedin, Doxorubicin and Olaratumab in Patients With Metastatic or Recurrent Leiomyosarcoma Trabectedin, Doxorubicin, Olaratumab - Leiomyosarcoma | Phase 1 | Withdrawn | University of Miami | 2019-06-01 | 2019-03-18 | |
| Talimogene Laherparepvec, Nivolumab and Trabectedin for Sarcoma Talimogene Laherparepvec 100000000 PFU/1 ML Injection Suspension [IMLYGIC], Nivolumab IV Soln 100 MG/10ML, Trabectedin 0.25 MG/1 VIAL Intravenous Powder for Solution - Sarcoma | Phase 2 | Recruiting | Sarcoma Oncology Research Center, LLC | 200 | 2019-05-15 | 2025-02-24 |
Showing 20 of 88. Sign in to see all of them.
Sarcoma (37) · Ovarian Neoplasms (15) · Leiomyosarcoma (12) · Liposarcoma (10) · Neoplasms (7) · Liposarcoma, Myxoid (4) · Neoplasm Metastasis (4) · Sarcoma, Ewing (4) · Breast Neoplasms (3) · Histiocytoma, Malignant Fibrous (3) · Rhabdomyosarcoma (3) · Sarcoma, Synovial (3) · Bone Neoplasms (2) · Endometrial Neoplasms (2) · Fallopian Tube Neoplasms (2)
Johnson & Johnson Pharmaceutical Research & Development, L.L.C. (11) · Italian Sarcoma Group (8) · European Organisation for Research and Treatment of Cancer - EORTC (5) · Janssen Research & Development, LLC (5) · Mario Negri Institute for Pharmacological Research (5) · Grupo Espanol de Investigacion en Sarcomas (4) · Gustave Roussy, Cancer Campus, Grand Paris (3) · M.D. Anderson Cancer Center (3) · Sarcoma Oncology Research Center, LLC (3) · Children's Oncology Group (2) · Fondazione Policlinico Universitario Agostino Gemelli IRCCS (2) · Fred Hutchinson Cancer Center (2) · Grupo Español de Investigación en Cáncer de Ovario (2) · Gynecologic Oncology Group (2) · Memorial Sloan Kettering Cancer Center (2)
United States (37) · Italy (22) · France (20) · Germany (20) · Spain (19) · Belgium (11) · Canada (9) · United Kingdom (9) · Netherlands (7) · Poland (6) · Australia (5) · Austria (5) · Russia (5) · Switzerland (5) · Israel (4)
Bradley J. Monk, MD (2) · Domenica Lorusso, Prof. (2) · Federica Grosso, MD (2) · Sant P Chawla, MD (2) · Seth Pollack (2) · Silvia Stacchiotti, MD (2) · Sylvain Baruchel, MD (2) · Andres Poveda, Ph.M. (1) · Angiolo Gadducci, MD (1) · Antonio Casado (1) · Axel Le Cesne, MD (1)
PMID 33960681, PMID 10655437, PMID 11165136, PMID 11304695, PMID 11479630, PMID 23397080, PMID 23410977, PMID 29177975, PMID 37407274, PMID 10500494, PMID 11063636, PMID 15177491, PMID 15350372, PMID 15659504, PMID 15701855, PMID 15721404, PMID 16271748, PMID 16912194, PMID 17290061, PMID 17395252, PMID 17822748, PMID 17936342, PMID 18378136, PMID 18755503, PMID 19556318, PMID 19652065, PMID 20647340, PMID 21144560, PMID 21376569, PMID 21642514, PMID 21739119, PMID 21835933, PMID 21996263, PMID 22088484, PMID 22293175, PMID 22541893, PMID 22765965, PMID 23385197, PMID 24512981, PMID 24692579, PMID 25100135, PMID 25239225, PMID 25341582, PMID 25591040, PMID 25680558, PMID 25795402, PMID 26351345, PMID 26371143, PMID 27078728, PMID 27733375
2009 (3), 2014 (2), 2016 (2), 2017 (2), P30CA015704 (2), 2004 (1), 2008 (1), 2023 (1), P30CA016672 (1), U01CA236220 (1), U10CA098543 (1), U10CA180821 (1)